Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Language
Publication year range
1.
Int Ophthalmol ; 42(1): 167-175, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34426862

ABSTRACT

PURPOSE: To evaluate the effect of subcutaneous omalizumab therapy on the allergic conjunctivitis symptoms of patients being treated for asthma. METHODS: A total of 84 eyes of 42 patients who were receiving subcutaneous omalizumab therapy for asthma and complained of allergic conjunctivitis symptoms underwent complete ophthalmic examination. All of the patients were graded according to signs and symptoms and duration of symptoms, evaluated using an ocular severity index (SI) and quality of life questionnaires. Immunoglobulin E (IgE) levels and both initial and final %FEV1 (forced expiratory volume in the first second) values were also evaluated. p values < 0.05 were accepted as statistically significant. RESULTS: The study included 36 women (85.7%) and 6 men (14.3%) with a mean age of 54.5 ± 10.8 years. The mean duration of omalizumab therapy was 46 ± 30.9 months. There were statistically significant changes between initial and final values for ocular SI, quality of life, subjective symptom frequency and severity and %FEV1. Final values of SI, quality of life, and symptom severity and frequency were statistically significantly lower compared to initial values, while final %FEV1 was statistically significantly higher compared to initial value (p < 0.001). CONCLUSION: Omalizumab therapy for asthma had a favorable effect on the patients' allergic conjunctivitis symptoms and decreased parameters related to ocular disease severity, improved quality of life and increased %FEV1values. TRIAL REGISTRATION NUMBER: 2019/5-5, Trial Registration Date: 28/03/2019, Retrospectively registered.


Subject(s)
Asthma , Conjunctivitis, Allergic , Adult , Aged , Asthma/drug therapy , Conjunctivitis, Allergic/diagnosis , Conjunctivitis, Allergic/drug therapy , Female , Humans , Male , Middle Aged , Omalizumab/therapeutic use , Quality of Life , Treatment Outcome
2.
Dis Markers ; 2018: 9131432, 2018.
Article in English | MEDLINE | ID: mdl-29692871

ABSTRACT

BACKGROUND: We aimed in our study to research the role of new cytokines such as IL-35, IL-22, and IL-17 that may form a target for novel treatment approaches. METHODS: IL-10, IL-17, TGF-ß, IFN-γ, IL-22, and IL-35 serum levels of allergic rhinitis (AR) patients were measured using ELISA method. Allergic sensitization was demonstrated by the skin prick test. Patients only with olive tree sensitivity were evaluated for seasonal AR (SAR). Patients only with mite sensitivity were included in the study for perennial AR (PAR). AR clinic severity was demonstrated by the nasal symptom scores (NSS). RESULTS: In total, 65 AR patients (patient group), having 31 PAR and 34 SAR patients, and 31 healthy individuals (control group) participated in the study. Cytokine levels between the patient group and the control group were compared; IL-17 (p = 0.038), IL-22 (p = 0.001), and TGF-ß (p = 0.031) were detected as high in the patient group, and IFN-γ (p < 0.001) was detected as low in the patient group. When correlation analysis was made between age, gender, prick test result, NSS, AR duration, and cytokine levels in the patient group, a negative correlation was detected only between IFN-γ (p = 0.032/r = -0.266) level and NSS. CONCLUSIONS: Accompanied by the literature information, these results made us think that T cell subgroups and cytokines have an important role in AR immunopathogenesis. It is thought that future studies to be conducted relating to this subject will form new targets in treatment.


Subject(s)
Interferon-gamma/blood , Interleukins/blood , Rhinitis, Allergic/blood , Tumor Necrosis Factor-alpha/blood , Adult , Biomarkers/blood , Female , Humans , Male
3.
Transplant Proc ; 47(5): 1360-3, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25964218

ABSTRACT

INTRODUCTION: We evaluated the relationship of interleukin-10 (IL-10) and transforming growth factor-ß (TGF-ß) levels with graft function in kidney transplantation patients receiving tacrolimus-based immunosuppression during the early post-transplantation period. MATERIAL AND METHODS: There were 112 patients who underwent kidney transplantation from live donors between May 2011 and May 2013. Eight patients had at least 1 of the exclusion criteria, and the remaining 104 patients were included in the study. The recipients underwent evaluation for biochemical markers, complete blood count, and creatinine and cytokine (IL-10, TGF-ß) levels during the pretransplantation and post-transplantation 6 months. RESULTS: The creatinine level was negatively correlated with IL-10 and positively correlated with TGF-ß levels in both the pretransplantation and early post-transplantation period. CONCLUSION: Low serum TGF-ß and high IL-10 levels at post-transplantation month 6 might have a positive effect on graft survival in living donor kidney recipients on tacrolimus-based immunosuppressive treatment.


Subject(s)
Interleukin-10/blood , Kidney Failure, Chronic/surgery , Kidney Transplantation , Transforming Growth Factor beta/blood , Adult , Biomarkers/blood , Creatinine/blood , Cytokines/blood , Female , Graft Survival , Humans , Immunosuppression Therapy , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/blood , Living Donors , Male , Middle Aged , Tacrolimus/therapeutic use
4.
Allergol. immunopatol ; 42(6): 573-579, nov.-dic. 2014. tab
Article in English | IBECS | ID: ibc-130148

ABSTRACT

BACKGROUND: No data are available on the incidence of drug hypersensitivity (DH) reactions in outpatient settings of tertiary allergy/immunology clinics. Our aims were to document the frequency of outpatient hospital admissions due to DH reactions to allergy/immunology clinics in adults and the management of these reactions in real life. We also investigated whether drug allergy affected social and medical behaviours of the patients. METHODS: This multi-centre study was performed for one year with the participation of 11 out of 16 tertiary allergy/clinical immunology clinics in Turkey. The study group consisted of the patients with DH reactions. Results of a questionnaire including drug reactions and management were recorded. RESULTS: Among 54,863 patients, 1000 patients with DH were enrolled with a median of 2.1% of all admissions. In real life conditions, the majority of approaches were performed for finding safe alternatives (65.5%; 1102 out of 1683) with 11.7% positivity. Diagnostic procedures were positive in 27% (154/581) of the patients. The majority of the patients had higher VAS scores for anxiety. A total of 250 subjects (25%) reported that they delayed some medical procedures because of DH. CONCLUSION: Our results documented the frequency of admissions due to DH reactions to allergy/clinical immunology clinics for the first time. Although physicians mostly preferred to perform drug tests in order to find safe alternatives, considering the fact that DH was confirmed in 27% of the patients, use of diagnostic tests should be encouraged, if no contraindication exists in order to avoid mislabelling patients as DH


No disponible


Subject(s)
Humans , Drug Hypersensitivity/epidemiology , Drug-Related Side Effects and Adverse Reactions/epidemiology , Turkey/epidemiology , /statistics & numerical data , Skin Tests , Health Surveys/statistics & numerical data
5.
Allergol Immunopathol (Madr) ; 42(6): 573-9, 2014.
Article in English | MEDLINE | ID: mdl-24269184

ABSTRACT

BACKGROUND: No data are available on the incidence of drug hypersensitivity (DH) reactions in outpatient settings of tertiary allergy/immunology clinics. Our aims were to document the frequency of outpatient hospital admissions due to DH reactions to allergy/immunology clinics in adults and the management of these reactions in real life. We also investigated whether drug allergy affected social and medical behaviours of the patients. METHODS: This multi-centre study was performed for one year with the participation of 11 out of 16 tertiary allergy/clinical immunology clinics in Turkey. The study group consisted of the patients with DH reactions. Results of a questionnaire including drug reactions and management were recorded. RESULTS: Among 54,863 patients, 1000 patients with DH were enrolled with a median of 2.1% of all admissions. In real life conditions, the majority of approaches were performed for finding safe alternatives (65.5%; 1102 out of 1683) with 11.7% positivity. Diagnostic procedures were positive in 27% (154/581) of the patients. The majority of the patients had higher VAS scores for anxiety. A total of 250 subjects (25%) reported that they delayed some medical procedures because of DH. CONCLUSION: Our results documented the frequency of admissions due to DH reactions to allergy/clinical immunology clinics for the first time. Although physicians mostly preferred to perform drug tests in order to find safe alternatives, considering the fact that DH was confirmed in 27% of the patients, use of diagnostic tests should be encouraged, if no contraindication exists in order to avoid mislabelling patients as DH.


Subject(s)
Anxiety Disorders/epidemiology , Drug Hypersensitivity/epidemiology , Hospitals, Special/statistics & numerical data , Patient Admission/statistics & numerical data , Tertiary Healthcare/statistics & numerical data , Administration, Oral , Adult , Allergens/adverse effects , Allergens/immunology , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Drug Hypersensitivity/diagnosis , Female , Humans , Immunization , Male , Perception , Turkey , beta-Lactams/adverse effects , beta-Lactams/therapeutic use
6.
Allergol Immunopathol (Madr) ; 37(6): 293-7, 2009.
Article in English | MEDLINE | ID: mdl-19913986

ABSTRACT

BACKGROUND: The aim of the present study was to develop the Turkish version of Rhinitis Quality of Life Questionnaire (RQLQ) and mini-RQLQ for clinical and research purposes. METHODS: Study included 55 patients with Allergic Rhinitis (AR), aged 18-69. Demographic characteristics and symptom score (T4SS) were recorded. All patients filled in the Turkish RQLQ and mini-RQLQ. Reliability analysis included internal consistency and item-total score correlations. Construct validity analysis was performed by Known Group method by correlation of RQLQ and mini-RQLQ scores with T4SS and SF36. RESULTS: Mean age of patients was 36.4+/-10.6. Mean T4SS was 4.7+/-4.1. Cronbach's alpha scores of all RQLQ domains were above 0.90 and those of mini-RQLQ were above 0.80. All items were significantly correlated with their domains. All correlation coefficients for item versus domain score were above 0.75 for RQLQ and above 0.84 for mini-RQLQ. Total RQLQ score was correlated with SF36 domains except physical functioning domain. Total mini-RQLQ score was significantly correlated with all SF36 domains (all r>-0.46). T4SS revealed significant correlation with RQLQ practical score (r=0.38). On the other hand, T4SS was correlated significantly with practical, nose and total scores of mini-RQLQ (r=0.33, 0.48, 0.34 respectively). CONCLUSIONS: Health is the complete state of well-being and AR has major impact on quality of life (QoL), therefore it seems essential to include QoL measures in clinical evaluation along with traditional parameters. This study has demonstrated that RQLQ and mini-RQLQ are valid measures for use in Turkish patients with AR.


Subject(s)
Quality of Life , Rhinitis, Allergic, Perennial/psychology , Rhinitis, Allergic, Seasonal/psychology , Surveys and Questionnaires , Adolescent , Adult , Aged , Educational Status , Female , Humans , Male , Middle Aged , Reproducibility of Results , Rhinitis, Allergic, Perennial/diagnosis , Rhinitis, Allergic, Seasonal/diagnosis , Turkey , Young Adult
7.
Clin Exp Allergy ; 37(8): 1183-8, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17651148

ABSTRACT

BACKGROUND: There is a difference in the extent of remodelling in allergic rhinitis (AR) and asthma. This may be attributed to the difference in local tissue response to these mediators. OBJECTIVES: The aim of this study was to compare vascular endothelial growth factor (VEGF) and its receptor foetal liver kinase (Flk)-1 expression between seasonal AR patients with or without asthma and non-allergic controls as well as that between AR patients with and without asthma. METHODS: Thirteen subjects with seasonal AR and six non-allergic controls were included in the study. Allergic sensitization was demonstrated by a skin prick test. Inferior turbinate thiny biopsies were obtained from both groups. Monoclonal mouse antibodies were used to demonstrate VEGF and Flk-1. Nasal mucosal endothelial cells' staining intensity was graded semi-quantitatively and the histochemical score (HSCORE) was calculated. In all samples, VEGF- and Flk-1-labelled vessels were counted for the assessment of vascular surface density (VSD). RESULTS: The mean HSCORE for VEGF and anti-VEGF-based VSD were significantly higher in the patient group (P=0.001 and 0.002, respectively). The mean HSCORE for Flk-1 and anti-Flk-1-based VSD in the patient group were significantly higher than those in the control group (P=0.016 and 0.028, respectively). Differences between the mean HSCORE for VEGF and anti-VEGF-based VSD in patients with pure AR and AR and asthma were insignificant (P=0.16 and 0.39, respectively). The mean HSCORE for Flk-1 and anti-Flk-1-based VSD in patients with pure AR were significantly lower than those in patients with AR and asthma (P=0.004 and 0.018, respectively). CONCLUSION: Angiogenic factor VEGF and its receptor Flk-1 is increased in AR. A similar increase in VEGF in AR with and without asthma despite a higher Flk-1 in AR patients with asthma may be a possible explanation for the presence of angiogenesis in the airway wall in patients with asthma but not in those with pure AR.


Subject(s)
Asthma/metabolism , Gene Expression Regulation , Nasal Mucosa/metabolism , Neovascularization, Pathologic/metabolism , Rhinitis, Allergic, Seasonal/metabolism , Vascular Endothelial Growth Factor A/biosynthesis , Vascular Endothelial Growth Factor Receptor-2/biosynthesis , Adolescent , Adult , Asthma/complications , Asthma/pathology , Female , Humans , Immunohistochemistry , Male , Nasal Mucosa/pathology , Neovascularization, Pathologic/complications , Neovascularization, Pathologic/pathology , Rhinitis, Allergic, Seasonal/complications , Rhinitis, Allergic, Seasonal/pathology , Skin Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...